Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Caribou Biosciences ( (CRBU) ).
On March 31, 2026, Caribou Biosciences announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma, reflecting promising early clinical data and a significant unmet need in access to CAR-T treatments. The designation, based on strong phase 1 CaMMouflage trial dose-escalation results including high response rates and a manageable safety profile, is expected to streamline CB-011’s development and review, reinforcing Caribou’s position in off-the-shelf cell therapies and underscoring potential benefits for multiple myeloma patients who currently struggle to obtain timely CAR-T care.
In the CaMMouflage phase 1 trial, 48 patients have been treated, and at the recommended expansion dose CB-011 showed a 92% overall response rate, a 75% rate of complete responses or better, and 91% minimal residual disease negativity in a 12-patient BCMA-naïve cohort as of a September 24, 2025 data cutoff. Investigators reported no graft-versus-host disease or certain serious neurologic toxicities, while common treatment-emergent adverse events such as cytopenias, infections, and cytokine release syndrome remained manageable, supporting continued dose expansion in both BCMA-naïve and BCMA-exposed patients under the RMAT-enabled pathway.
The most recent analyst rating on (CRBU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.
Spark’s Take on CRBU Stock
According to Spark, TipRanks’ AI Analyst, CRBU is a Neutral.
The score is primarily constrained by weak financial performance, including a 2025 revenue collapse, persistent large losses, and significant ongoing cash burn with declining equity. Technical indicators are neutral-to-mixed and provide only limited support, while valuation is not compelling due to negative earnings and no dividend.
To see Spark’s full report on CRBU stock, click here.
More about Caribou Biosciences
Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company developing off-the-shelf CAR-T cell therapies for hematologic malignancies. Leveraging its chRDNA genome-editing platform for enhanced precision and immune cloaking, Caribou is focused on products such as vispacabtagene regedleucel and CB-011 to expand rapid access to transformative treatments for patients with devastating diseases.
Average Trading Volume: 1,226,819
Technical Sentiment Signal: Sell
Current Market Cap: $166.2M
See more data about CRBU stock on TipRanks’ Stock Analysis page.